Bolstered by early funding from BrightFocus, a promising new treatment for individuals suffering from stroke, concussion, and traumatic brain injury—known risk factors for dementia—has received approval from the @FDA to move into Phase 2 clinical trials. bit.ly/4aBF4Hl
0
1
1
597
0
Download Image